首页> 外文期刊>BMC Pediatrics >Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis
【24h】

Varicella-zoster virus infections in immunocompromised patients - a single centre 6-years analysis

机译:免疫功能低下患者的水痘带状疱疹病毒感染-单中心6年分析

获取原文
           

摘要

Background Infection with varicella-zoster virus (VZV) contemporaneously with malignant disease or immunosuppression represents a particular challenge and requires individualized decisions and treatment. Although the increasing use of varicella-vaccines in the general population and rapid initiation of VZV-immunoglobulins and acyclovir in case of exposure has been beneficial for some patients, immunocompromised individuals are still at risk for unfavourable courses. Methods In this single center, 6-year analysis we review incidence, hospitalization and complication rates of VZV-infections in our center and compare them to published data. Furthermore, we report three instructive cases. Results Hospitalization rate of referred children with VZV-infections was 45%, among these 17% with malignancies and 9% under immunosuppressive therapy. Rate of complications was not elevated in these two high-risk cohorts, but one ALL-patient died due to VZV-related complications. We report one 4-year old boy with initial diagnosis of acute lymphoblastic leukemia who showed a rapidly fatal outcome of his simultaneous varicella-infection, one 1.8-year old boy with an identical situation but a mild course of his disease, and an 8.5-year old boy with a steroid-dependent nephrotic syndrome. This boy developed severe hepatic involvement during his varicella-infection but responded to immediate withdrawl of steroids and administration of acyclovir plus single-dose cidofovir after nonresponse to acyclovir after 48 h. Conclusion Our data show that patients with malignant diseases or immunosuppressive therapy should be hospitalized and treated immediately with antiviral agents. Despite these measures the course of VZV-infections can be highly variable in these patients. We discuss aids to individual decision-making for these difficult situations.
机译:背景技术同时感染水痘带状疱疹病毒(VZV)和恶性疾病或免疫抑制是一个特殊的挑战,需要个性化的决策和治疗。尽管在一般人群中水痘疫苗的使用增加以及在接触情况下快速启动VZV-免疫球蛋白和无环鸟苷对某些患者是有益的,但免疫功能低下的个体仍面临病程不利的风险。方法在这个单一的中心进行为期6年的分析,我们回顾了该中心VZV感染的发生率,住院率和并发症发生率,并将其与已发表的数据进行了比较。此外,我们报告了三个教学案例。结果转介VZV感染儿童的住院率为45%,其中恶性肿瘤占17%,免疫抑制治疗占9%。在这两个高危人群中,并发症的发生率没有升高,但是一名ALL患者因VZV相关并发症而死亡。我们报告了一名4岁男孩,其最初诊断为急性淋巴细胞白血病,显示出其同时发生水痘感染迅速致命的结果; 1名1.8岁男孩,其情况相同,但病情较轻; 8.5-岁的男孩患有类固醇依赖型肾病综合征。这个男孩在水痘感染期间出现了严重的肝脏受累,但在48小时后对阿昔洛韦无反应后,对立即停用类固醇和给予阿昔洛韦加单剂量西多福韦有反应。结论我们的数据表明,患有恶性疾病或免疫抑制治疗的患者应住院治疗并立即用抗病毒药治疗。尽管采取了这些措施,这些患者的VZV感染过程仍可能高度可变。我们讨论了针对这些困难情况的个人决策帮助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号